Metastatic Castration-resistant Prostate Cancer
Conditions
Keywords
RC48-ADC, metastasis Castration Resistant Prostate Cancer, HER2
Brief summary
This is a single-arm, open, single-center clinical study to evaluate the efficacy and safety of RC48-ADC in patients with mCRPC who have progressed after NHT. A total of 40 patients with mCRPC with immunohistochemically confirmed HER2 expression who had progressed after treatment with at least one novel endocrine therapy will be included in this study.
Detailed description
This is a single-arm, open, single-center clinical study to evaluate the efficacy and safety of RC48-ADC in patients with mCRPC who have progressed after NHT. A total of 40 patients with mCRPC with immunohistochemically confirmed HER2 expression who had progressed after treatment with at least one novel endocrine therapy will be included in this study. Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death. During the treatment, participants will evaluate every 4 weeks, including PSA testing every 4 weeks and tumor evaluation according to PCWG3 standards every 8 weeks. If the patient develops disease progression, the treatment will be discontinued and survival follow-up will be conducted every 8 weeks.
Interventions
DRUGDisitamab Vedotin（RC48-ADC）
Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
Sponsors
Peking University Cancer Hospital & Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\) Prostate cancer confirmed by histology; * 2\) ≥ 18 years old; * 3\) The presence of metastatic lesions confirmed by bone scan and/or CT/MRI and/or PET-CT; * 4\) ECOG score 0-2; * 5\) Continuously maintain ADT treatment and maintain testosterone levels ≤ 50ng/dL; The progression of prostate cancer recorded within 6 months prior to screening; * 6\) Having received at least one NHT in the past before progressing; * 7\) HER2 IHC 1+, 2+, or 3+; * 8\) Inability to or refusal docetaxel chemotherapy; * 9\) Voluntarily join the study; * 10\) Expected survival time ≥ 6 months; * 11\) Normal function of main organs;
Exclusion criteria
* 1)Have a history of malignant tumors other than prostate cancer; * 2)Previously received allogeneic stem cell or parenchymal organ transplantation; * 3\) Previously or currently suffering from congenital or acquired immunodeficiency diseases; * 4\) The patient have a history of allergy to RC48 or paclitaxel, or a history of Hypersensitivity to chimeric or humanized antibodies or fusion proteins, or allergy to excipients of the study drug; * 5\) Other significant clinical and laboratory abnormalities that affect safety evaluation; * 6\) Those who are unwilling or unable to take effective contraceptive measures; * 7\) Subjects with active brain metastasis;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PSA response rate | 24 months | The proportion of subjects receiving at least one cycle of treatment with the study drug who had at least a 50% reduction in PSA from baseline and maintained it for more than 21 days (PSA50). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR，Objective Response Rate | 24 months | The proportion of patients who achieved patial response and complete reponse. |
| Overall survival (OS) | From the first dose to death from any cause，up to two years. | median OS or OS rate |
| Progression free survival | From the first dose to the first documentation of disease progression or death, up to two years. | median PFS or PFS rate |
Contacts
Primary ContactYudong Cao, Doctor
Outcome results
None listed